FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 17, 2023
app pub date -
Jun 29, 2021
filing date -
Jun 30, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a fusion protein comprising an anti-LAG-3 antibody and IL-2 or a variant thereof. In the fusion protein according to the present invention, the anti-LAG-3 antibody moiety may bind to LAG-3, thereby regulating the binding of LAG-3 and MHCII. Moreover, the IL-2 protein or a variant thereof may regulate the activity of T cells. Therefore, a pharmaceutical composition comprising the fusion protein increases the immune activity in vivo and can be effectively used as an anticancer agent, and thus is highly industrially applicable.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully